ICM
HBIO icon

Invenomic Capital Management’s Harvard Bioscience HBIO Stock Holding History

Invenomic Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-49,156
Closed -$1.09M – 165
2020
Q1 		$1.09M Sell
49,156
-20,055
-29% -$543K 0.89% 40
2019
Q4 		$2.11M Buy
+69,211
New +$1.99M 0.85% 50

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Invenomic Capital Management's HBIO Position: Q2 2020 in Review

Invenomic Capital Management sold out of Harvard Bioscience (HBIO) in Q2 2020, closing a stake of 49,156 shares — an estimated $1.09M sold.

Invenomic Capital Management first reported a position in HBIO in Q4 2019 and held it in 2 quarters. The position peaked at $2.11M in Q4 2019. 87 funds tracked by Wall St. Rank hold HBIO as of Q2 2020.

  • Invenomic Capital Management reported no remaining Harvard Bioscience position as of Q2 2020 after selling out during the quarter.
  • Invenomic Capital Management sold 49,156 Harvard Bioscience shares in Q2 2020, an estimated $1.09M.
  • Invenomic Capital Management first reported a position in Harvard Bioscience in Q4 2019 and held it in 2 quarters.
  • Invenomic Capital Management's Harvard Bioscience position peaked at $2.11M in Q4 2019.
  • 87 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2020.

Based on Invenomic Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.